Veru (NASDAQ:VERU – Get Free Report) released its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%.
Veru Stock Down 4.5 %
NASDAQ VERU opened at $0.53 on Friday. Veru has a 52 week low of $0.37 and a 52 week high of $1.92. The company has a fifty day moving average of $0.72 and a two-hundred day moving average of $0.77.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on VERU. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Veru in a research report on Thursday, January 2nd. Oppenheimer reiterated an “outperform” rating and set a $5.00 price objective on shares of Veru in a research report on Tuesday, November 5th.
About Veru
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
- Five stocks we like better than Veru
- Profitably Trade Stocks at 52-Week Highs
- Cisco Roars Back: Is the Tech Giant Reborn?
- Investing in Travel Stocks Benefits
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Forget Tesla: 3 Stocks to Ride the Elon Musk Effect
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
